<DOC>
	<DOCNO>NCT00673387</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled , dose-ranging study examine safety , tolerability effect body weight range dos metreleptin pramlintide , administer separate subcutaneous ( SC ) injection obese overweight subject .</brief_summary>
	<brief_title>Study Examine Safety , Tolerability , Effect Body Weight Metreleptin Administered Conjunction With Pramlintide Obese Overweight Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>18 65 year old . Is obese ( Body Mass Index [ BMI ] &gt; =30kg/m^2 &lt; =35kg/m^2 ) ; overweight ( BMI &gt; =27kg/m^2 &lt; 30kg/m^2 . Has stable body weight , i.e. , vary &gt; 3 % within 3 month prior study . Has treat past 3 month currently treat follow medication : Oral contraceptive ( female subject ) ; Hormone replacement therapy ( female subject ) ; Metformin treatment polycystic ovary syndrome ( female subject ) ; Antihypertensive agent ; Lipidlowering agent ; Thyroid replacement therapy ; selective serotonin reuptake inhibitor ( SSRIs ) . Is comfortable repeat telephone contact lifestyle counselor study . Is nonsmoker ( smoke least 6 month prior study ) . Has medical history ( e.g. , morbid childhood obesity ) and/or physical characteristic suggestive genetic obesity syndromatic obesity ( e.g. , PraderWilli syndrome , BardetBiedl syndrome ) . Is currently enrol plan enroll diet , weight loss , exercise program specific intent lose weight ( subject follow exercise regimen result stable weight maintenance least 2 month prior enrollment eligible study inclusion ) Has treat past 2 month , currently treat , expect require undergo treatment *antiobesity agent ( prescription overthecounter ) , *antipsychotic agent , *antiepileptic agent , *antidepressant agent , *drugs directly affect gastrointestinal motility , *antidiabetic medication . Has previously receive treatment metreleptin pramlintide clinical study receive prior treatment pramlintide ( SYMLINÂ® ) . Has receive investigational drug within 30 day within period correspond 5 halflives drug , whichever great , prior study start . Has major surgery blood transfusion , donate blood past 2 month plan donate blood study . Has liposuction , abdominoplasty , similar procedure past year planning procedure study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>overweight</keyword>
	<keyword>obesity</keyword>
	<keyword>pramlintide</keyword>
	<keyword>metreleptin</keyword>
	<keyword>Amylin</keyword>
</DOC>